KUALA LUMPUR, 15 October 2020 – Wuhan Easydiagnosis Biomedicine Co Ltd (“Wuhan Easydiagnosis”), a leading manufacturer of in-vitro diagnostic devices based in Wuhan, China and specialising in the development, production, and distribution of point-of-care testing (“POCT”) or bedside testing rapid diagnostic reagents and related equipment to more than 20 countries, has authorized HWGB Biotech Sdn Bhd (fka HWG Consortium Sdn Bhd) (“HWGB Biotech”), a wholly-owned subsidiary of Ho Wah Genting Berhad (“HWGB” or the “Company”) (Bursa Stock Code: 9601) as the distributor of its COVID-19 nucleic acid test kits and nucleic acid extraction reagents in Malaysia with a validity period from 20 March 2020 to 20 March 2021.
On 13th October 2020, it was announced that the MOH had, in a technical report, shown that the COVID-19 test kits passed with 100% accuracy the sensitivity tests administered by the MOH.
Wuhan Easydiagnosis, listed on the Shezhen Stock Exchange, an exchange well-known for listings of high-growth technology start-ups, has a strong research and development team together with 100,000 production lines in international-grade workshops. It is also the first manufacturer of bedside, rapid and quantitative blood-detectors in China while more than 30 of its POCT products are registered with China’s State Food and Drug Administration. It is also a provider of intelligent management systems to hospitals of cardiovascular, kidney, infectious, endocrine and metabolic diseases; obstetrics and gynecology, and eugenics; physical examination and other comprehensive solutions.
General Manager, Medical & Pharmaceutical Research of HWGB Biotech, Dr. Yaman Walid Kassab (“Dr. Yaman”) said: “We value our partnership with Wuhan Easydiagnosis, a maker of globally recognised medical diagnostics kits. The MOH’s positive evaluation on the COVID-19 test kits that we are authorised to distribute is a strong testament to the robustness and reliability of the test kits”.
“We believe that our relationship with Wuhan Easydiagnosis will grow from strength to strength as we work together and explore other avenues of collaboration in Malaysia and Southeast Asia”, Dr. Yaman added.
ABOUT HO WAH GENTING BERHAD
Ho Wah Genting Berhad (“HWGB” or the “Company”) is principally engaged in investment holdings and the provision of management services to its subsidiaries. The Company had on 30 June 2020 diversified its existing businesses to include healthcare-related industry which is mainly involved in Health Supplement, Biotechnology, and Health Technology. In addition, the Company and its subsidiaries (“HWGB Group” or the “Group”) are also engaging in the businesses of Investment holdings; manufacturing of wires and cables and moulded power supply cord sets and cable assemblies for electrical and electronic devices and equipment; Trading of wires and cables; and travel agent and tour related services.
For more information on about HWGB Biotech, follow us on https://hwgbbiotech.com, http://subscription.hwgbbiotech.com, https://www.facebook.com/hwgbbiotech, https://www.linkedin.com/company/hwgbbiotech and https://t.me/hwgbbiotech to view the latest updates about our company ventures in the healthcare industry.
Dr.Yaman Walid Kassab is an Assistant Professor of Clinical Pharmacy. He obtained his PhD in Clinical Pharmacy at University Science Malaysia (USM) in 2013. He possesses 7 years of experience in academia, specifically in the pharmacotherapy field. He is actively involved in medical research and publication and has published more than 40SCOPUS/ISI indexed research papers and has supervised more than 50 research projects and 20 postgraduate research students. He is also serving as an editorial Board member of several reputed international journals like “Frontiers in Pharmacology”, “Archives of Pharmacy Practice (APP)” , “Journal of Medical and Pharmaceutical Innovation (JMPI)” , ”Annals of Cardiology and Cardiovascular Diseases” , “Updates in Public Health and Preventive Medicine” He has been a member of many international professional bodies such as International Association of Therapeutic Drug Monitoring & Clinical Toxicology in CANADA, Syndicate of Syrian Pharmacists, Malaysian Association of Education in Medicine & Health Sciences, Malaysian Pharmaceutical Society.
Wuhan Easydiagnosis Biomedicine Co Ltd (SHE: 002932)
Wuhan Easy Diagnosis Biomedicine Co., Ltd, Located in the National Biological Industry Base in Wuhan province, China. The Company is a leading IVD manufacturer, specializing in the development, production and sales of POCT rapid diagnostic reagents and related equipment.
Equipped with a strong and professional R&D team, with 100,000 grade clean workshop and international leading production lines. All of the company product lines have been gotten ISO13485：2016, CE certification, and more than 30 parameters of POCT rapid diagnostic products with SFDA registration. Also, the Company is the first company making bedside, rapid and quantitative detection in whole blood in China and its products are selling in more than 20 countries. The Company intelligent management system provides hospital departments at all levels detections including cardiovascular disease, kidney disease, infectious disease, endocrine and metabolic diseases, obstetrics and gynaecology, and eugenics, physical examination, and other comprehensive solutions.